Abstract
Helinx™ technology uses the psoralen S-59 and ultraviolet A (UVA) light to inactivate a broad spectrum of bacteria, viruses, and leukocytes in platelet concentrates (PC). In a paired study we investigated the effect of the Helinx™ technology on platelet function over a storage period of 5 days. Double-dose apheresis PC (7.0 x 1011 platelets) resuspended in 35% plasma/65% platelet additive solution (PAS III) were collected (n = 8) and split into two equal size PC. One PC was not treated (Control), the other PC was treated with 150 µM S-59 and 3 Joules/cm2 UVA on Day 1 (Test).
After 5 days of storage, there were no statistically significant differences (p >0.05) between the Test PC and Control PC with respect to pH (7.0 vs 6.9), hypotonic shock response (HSR) (37% vs 36%), CD62 expression (29%o vs 28%), morphology score (307 vs 301), cell lysis by electron microscopy (15% vs 14%) and platelet count (868 vs 900 x 109/L). Lactate dehydrogenase (LDH) was increased (175 vs 104 IU/L) for Test PC vs Control PC.
These results demonstrate that double-dose collection of apheresis platelets can be treated with the Helinx™ technology as two products. In vitro quality of pathogen-inactivated split-dose PC did not differ significantly from Control PC over the storage period of 5 days.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Goldman M., Blajchman M.A. Blood product-associated bacterial sepsis. Transfus Med Rev 1991; 5:73–83.
Morrow J.F., Braine H.G., Kickler T.S., et al. Septic reactions to platelet transfusions. A persistent problem. JAMA 1991; 266:555–8.
Blajchman MA, Ali AM. Bacteria in the blood supply: an over-looked issue in transfusion medicine. In: Nance ST, ends Blood safety: current challenges. Bethesda: American Association of Blood Banks, 1992:213–28.
Lin, L., G.P. Wiesehahn, P.A. Morel, and L. Corash. Use of 8-methoxypsoralen and long-wavelength ultraviolet radiation for decontamination of platelet concentrates. Blood 1989; 74: 517–525.
Wagner SJ, White R, Wolf L, et al. Determination of residual 4’-aminomethyl-4.5’8-trimethylpsoralen and mutagenicity testing following psoralen plus UVA treatment of platelet suspension. Photochem Photobiol 1993; 57:819–24.
Cimino G, Gamper H, Isaacs ST, Hearst JE. Psoralens as photoactive probes of nucleic acid structure and function: organic chemistry, photochemistry, and biochemistry. Ann Rev Biochem 1985; 54:1151–1193.
Lin L, Alfonso R, Behrman B, et al. Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusion. Infusionsther Transfusionsmed 1998; 25:39–48.
Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in human platelet concentrates using a novel psoralen and long wavelength ultraviolet light. Transfusion 1997; 34:423–435.
Hei DJ, Grass J, Lin L, Corash L, Cimino G. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999; 39:239–248.
Heddle NM, Klama L, Singer J, Richards C, Fedak P, Walker I, Kelton JG: The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1995; 331: 625.
Spitzer TR: Transfusion induced graft-vs.-bone disease. “In Graft-vs.-disease. Immunology, Pathophysiology and Treatment”, Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): NY. Marcel Dekker. 1990, p 539.
Anderson KC: Clinical indications for blood components irradiation. “In Irradiation of blood components”, Bethesda MD, Baldwin ML, Jeffries LC (eds): American Association of Blood Banks. 1992, p. 31.
Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998; 91:2180–2188.
Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93:3140–3147.
Corash L, Behrman B, Rheinschmidt M, Wages D, Snyder E. Raife T, Kagen L, Baril L, Davis K, Metzel P, Walsh J, Smith D, Shafer S, Cimino G, Hei D, Lin L, and Buchholz DH. Post-transfusion viability and tolerability of photochemically treated platelet concentrates (PC). Blood 1997; 90: 267a.
Slichter, SJ, L. Corash, M. Grabowski, R. LeBlanc, J Sedgwick, D. Townsend-MaCall, K. Davis, B. Behrman, M Rheinschmidt, P. Metzel, L. Lin, and D.H. Buchholz. Viability and hemostatic function of photochemically treated (PCT) platelets (PLTS) in thrombocytopenic patients. Blood 1999; 94(S1): 376a.
Van Rhenen D, Gulliksson H, Pamphilon D, et al. S-59 (HELINX™) photochemically treated platelets (pit) are safe and effective for support of thrombocytopenia: Results of the euroSPRITE Phase 3 trial. Blood 2000; 96:819a (Abstract).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Janetzko, K., Corash, L., Lin, L., Flament, J., Klüter, H. (2002). In vitro Function of Double-Dose Platelets Treated with the Pathogen Inactivation Helinx™ Technology. In: Holick, M.F. (eds) Biologic Effects of Light 2001. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0937-0_32
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0937-0_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5313-3
Online ISBN: 978-1-4615-0937-0
eBook Packages: Springer Book Archive